Current market catalysts

Can-Fite BioPharma Says Blinded Overall Survival In Pivotal Phase 3 Namodenoson Liver Cancer Study Appears Longer Than Originally Anticipated; Evaluating Earlier Timing For Planned Interim Analysis

JP Morgan Upgrades Magnolia Oil & Gas to Overweight, Raises Price Target to $33

JP Morgan analyst Arun Jayaram upgrades Magnolia Oil & Gas (NYSE:MGY) from Neutral to Overweight and raises the price target from $32 to $33.

Lexaria Bioscience Announces Warrant Inducement Repricing 453,969 Warrants To $12.92/Share From Original Prices Of $17.85 To $45.90, For About $5.9M Gross Proceeds; Issues New Series A, Series B Warrants At $12.67/Share

GRI Bio Says Phase 2a GRI-0621 IPF Study Showed Placebo-Adjusted FVC Change Of +99 mL At Week 12, +139 mL On Background Antifibrotic Therapy; Says Data Supports Advancement Into Longer-Duration Study

Sensata Technologies Introduces OmniNode

Sensata’s new OmniNode simplifies commercial EV power distribution architecture by consolidating multiple high-voltage components into a single system.Integrates switching, protection, sensing, diagnostics,

JP Morgan Downgrades Gulfport Energy to Underweight, Lowers Price Target to $194

JP Morgan analyst Zach Parham downgrades Gulfport Energy (NYSE:GPOR) from Overweight to Underweight and lowers the price target from $240 to $194.

8-K filing — VERU INC. (VERU)

Filed: 2026-09-08 AccNo: 0001193125-26-384430 Size: 202 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Rothschild & Co Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $203

Rothschild & Co analyst Jamie Clark initiates coverage on Guardant Health (NASDAQ:GH) with a Buy rating and announces Price Target of $203.

FDA Approves Abbott’s TactiFlex Duo Ablation Catheter, Sensor Enabled To Treat Patients With Challenging Cases Of Atrial Fibrillation

Abbott's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ combines pulsed field ablation (PFA) and radiofrequency (RF) energy in a single catheter to treat complex atrial fibrillation (AFib) casesStrong clinical

8-K filing — GRI Bio, Inc. (GRI)

Filed: 2026-09-08 AccNo: 0001824293-26-000057 Size: 4 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

8-K filing — Parker-Hannifin Corp (PH)

Filed: 2026-09-08 AccNo: 0001193125-26-384428 Size: 142 KB Item 8.01: Other Events

S&P 500’s ‘Teflon’ Streak Has Reached 329 Sessions — Wall Street Warns These Risks Could Finally Break the Market

Despite the S&P 500's historic 329-session streak, HSBC and Deutsche Bank warn that stagflation and leverage threaten this "Teflon" market.

BMO Capital Downgrades Amgen to Market Perform, Maintains Price Target to $450

BMO Capital analyst Evan David Seigerman downgrades Amgen (NASDAQ:AMGN) from Outperform to Market Perform and maintains the price target from $450 to $450.

8-K filing — AGILENT TECHNOLOGIES, INC. (A)

Filed: 2026-09-08 AccNo: 0001193125-26-384426 Size: 186 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Bull of the Day: Marathon Petroleum (MPC)

Marathon Petroleum (MPC) is experiencing exceptional growth driven by record-high crack spreads in the refining industry. The company reported a 341% expected earnings increase for 2026, with a forward P/E of 8.2 despite shares reaching new highs. MPC has generated substantial cash flow, returning $2.8 billion to shareholders in Q2 2026 through dividends and buybacks. However, analysts caution this is a short-term opportunity dependent on volatile crack spreads.

Should Schwab U.S. Large-Cap Growth ETF (SCHG) Be on Your Investing Radar?

The Schwab U.S. Large-Cap Growth ETF (SCHG) is highlighted as an attractive option for investors seeking broad exposure to large-cap growth stocks. With $62.83 billion in assets, a low expense ratio of 0.04%, and a Zacks ETF Rank of 2 (Buy), SCHG offers diversified exposure to 197 holdings with heavy concentration in technology. The fund has returned 9.14% year-to-date and 15.78% over the past year, though it carries medium risk with a beta of 1.19.

Is Invesco Dorsey Wright Emerging Markets Momentum ETF (PIE) a Strong ETF Right Now?

The Invesco Dorsey Wright Emerging Markets Momentum ETF (PIE) is criticized as not suitable for investors seeking to outperform the Broad Emerging Market ETFs segment. Despite strong year-to-date returns of 45.67%, the fund carries a high expense ratio of 0.90% and medium risk profile. Analysts recommend cheaper alternatives like Vanguard Emerging Markets Stock Index Fund (VWO) and iShares Core MSCI Emerging Markets ETF (IEMG) for cost-conscious investors.

Should iShares Morningstar Small-Cap ETF (ISCB) Be on Your Investing Radar?

The iShares Morningstar Small-Cap ETF (ISCB) is reviewed as a passively managed small-cap blend ETF with a low expense ratio of 0.04%, $286.71 million in assets, and year-to-date performance of 16.7%. The fund holds approximately 1,580 stocks with heavy exposure to Industrials, Financials, and Healthcare sectors. It carries a Zacks ETF Rank of 3 (Hold) and is compared to larger competitors like Vanguard Morningstar Small-Cap ETF (VB) and iShares Core S&P Small-Cap ETF (IJR).

Is WisdomTree U.S. SmallCap Dividend ETF (DES) a Strong ETF Right Now?

The WisdomTree U.S. SmallCap Dividend ETF (DES) is analyzed as a smart beta ETF offering broad exposure to small-cap value stocks. With $2.2 billion in assets, a 0.38% expense ratio, and 2.27% dividend yield, DES has returned 22.24% year-to-date and 20.21% over 12 months. The fund holds 517 stocks with heavy Financials sector exposure (25.4%) and carries medium risk with a beta of 0.89. Cheaper alternatives like IWN (0.24% expense ratio) and VBR (0.05% expense ratio) are also available.

Should First Trust Mid Cap Core AlphaDEX ETF (FNX) Be on Your Investing Radar?

First Trust Mid Cap Core AlphaDEX ETF (FNX) is a passively managed mid-cap blend ETF with $1.39 billion in assets. While it has delivered solid returns of 15.45% year-to-date and 16.79% over the past year, its 0.62% expense ratio is relatively high compared to competitors. The ETF carries a Zacks ETF Rank of 3 (Hold) and is recommended primarily for long-term investors seeking mid-cap exposure, though alternatives like Vanguard Morningstar Mid-Cap ETF and iShares Core S&P Mid-Cap ETF offer significantly lower expense ratios.

Is Janus Henderson Small Cap Growth Alpha ETF (JSML) a Strong ETF Right Now?

JSML is a smart beta ETF launched in 2016 that seeks to outperform the small-cap growth segment through fundamental analysis of growth, profitability, and capital efficiency. With $367.94 million in assets, a 0.30% expense ratio, and year-to-date gains of 20.74%, it offers diversified exposure across 122 holdings with healthcare as the largest sector allocation. However, investors should consider lower-cost alternatives like IWO (0.24% expense ratio) and VBK (0.05% expense ratio) for potentially better value.

Should iShares Morningstar Small-Cap Value ETF (ISCV) Be on Your Investing Radar?

ISCV, a passively managed small-cap value ETF launched in 2004, offers broad exposure to the small-cap value segment with low costs (0.06% expense ratio) and strong year-to-date performance of 18.64%. The fund holds over 1,000 stocks with heavy allocation to Financials (24.6%) and has a Zacks ETF Rank of 2 (Buy), making it suitable for long-term investors seeking small-cap value exposure.

Is Invesco S&P MidCap 400 Pure Growth ETF (RFG) a Strong ETF Right Now?

Invesco S&P MidCap 400 Pure Growth ETF (RFG) is reviewed as a smart beta ETF offering mid-cap growth exposure with a 0.35% expense ratio. The fund has delivered 16.08% year-to-date returns and 18.85% over the past year, with 102 holdings primarily concentrated in Industrials (27.7%), Healthcare, and Information Technology sectors. It carries medium risk with a beta of 1.12, though cheaper alternatives like Vanguard Morningstar Mid-Cap Growth ETF (VOT) and iShares Russell Mid-Cap Growth ETF (IWP) are available.

Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?

The ALPS Medical Breakthroughs ETF (SBIO) is a passively managed healthcare ETF that tracks small-cap and mid-cap pharmaceutical and biotechnology stocks in Phase II or Phase III FDA clinical trials. With a 0.5% expense ratio, $243.54 million in assets, and 107 holdings, it has delivered 32.1% year-to-date returns and 82.83% over 12 months. However, it carries high risk with a beta of 0.74 and 30.54% standard deviation. The fund received a Zacks ETF Rank of 3 (Hold), with alternatives like VHT and XLV offering lower expense ratios.

Is State Street SPDR S&P Homebuilders ETF (XHB) a Strong ETF Right Now?

The State Street SPDR S&P Homebuilders ETF (XHB) is not recommended as a suitable option for investors seeking to outperform in the Industrials ETFs segment. The fund has declined 12.9% over the past year with high volatility (beta of 1.25, standard deviation of 26.77%), concentrated exposure with only 35 holdings, and a dividend yield of just 0.69%. Investors are advised to consider alternative options like market cap weighted ETFs or other homebuilder-focused funds.

Should Vanguard Morningstar Mid-Cap Growth ETF (VOT) Be on Your Investing Radar?

Vanguard Morningstar Mid-Cap Growth ETF (VOT) is highlighted as an attractive option for investors seeking mid-cap growth exposure. With $19.46 billion in assets, a low expense ratio of 0.05%, and a Zacks ETF Rank of 2 (Buy), VOT offers diversified exposure to 128 mid-cap growth companies. The fund has returned 7.86% year-to-date and 5.01% over the past year, with a beta of 1.16 indicating medium risk.

Bear of the Day: The Campbell's Co. (CPB)

Campbell's Company reported Q4 fiscal 2026 earnings miss and announced its first dividend cut since 2001, reducing the quarterly dividend by 36% to $0.25 per share to accelerate debt reduction. The company faces headwinds from inflation, supply chain costs, and tariffs, with net sales declining 8%. For fiscal 2027, Campbell's guided earnings to decline as much as 24%, below analyst consensus expectations. Shares are down 22.8% year-to-date and trading near 5-year lows.

Why USA Rare Earth Stock Surged 19.2% Last Month

USA Rare Earth stock gained 19.2% in August, driven primarily by the announcement of a $1.55 billion government-backed special purpose vehicle deal to support its acquisition of Brazilian rare-earth mining company Serra Verde. The company's Q2 earnings missed expectations, but the subsequent completion of the Serra Verde acquisition in September transformed its financial profile and positioned it for rapid scaling in the critical minerals sector.

Amwell Receives Letter of Intent from Department of Veterans Affairs to Help Power its Digital Health Infrastructure

Amwell announced that the Department of Veterans Affairs has declared its intent to deploy Amwell's virtual health platform across the VA enterprise to modernize its digital health infrastructure and serve over nine million Veteran beneficiaries. The Letter of Intent follows a comprehensive VA evaluation that determined Amwell's platform aligns with the Department's strategic objectives, particularly in scalable video consultations, interoperability, cybersecurity compliance, and integrated care delivery. However, the Letter of Intent is non-binding and any formal agreement is contingent upon contract negotiation and federal procurement requirements.

Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Fortress Biotech announced that CEO Lindsay A. Rosenwald will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The presentation will be available on-demand starting September 11, 2026, with one-on-one meetings scheduled for September 14-16, 2026. The company continues to advance its portfolio of marketed pharmaceutical products and development programs across oncology, dermatology, and rare diseases through partnerships with leading academic and biopharmaceutical institutions.